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Background/aim: This study was designed to investigate the efficacy of a new vaccine against breast cancer, which was made by mixing
the extract of heated 4T1 cells and naloxone, as an adjuvant.
Materials and methods: Female BALB/c mice of 6–8 weeks old were challenged subcutaneously in the right flanks with 4T1 cells.
When all animals developed a palpable tumor, immunotherapy was initiated. Mice in the experimental groups received, twice with a
1-week interval, either the extract of heated 4T1 alone or in combination with naloxone, and mice in the negative control group received
phosphate-buffered saline. One week after the last immunotherapy, half of the mice were euthanized in order to determine the immune
response profile. The remaining animals were kept until the time when death occurred spontaneously.
Results: The combined-treated mice with mammary tumors showed a more favorable survival curve and slower rate of tumor
development compared to the mice with tumors that received only heated 4T1 and/or negative control mice. Moreover, the combined
immunization significantly amplified the respiratory burst potential and the secretion of IFN-γ, and, conversely, diminished the
secretion of IL-4, IL-10, and TGF-β in the splenocyte population compared to splenocytes from other groups.
Conclusion: The combined naloxone and heated 4T1 cells promote beneficial outcomes in the mouse model of breast cancer.
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1. Introduction
It appears that the immune system has the ability to
recognize and eliminate some tumor cells, at least in the
early stages of their development (1). Nonetheless, many
tumors escape from the pressure of the immune system
and become clinically significant. Therefore, improvement
of immunity responses against tumor cells may be a
useful strategy to control malignancy (1–3). Therapeutic
cancer vaccines are one of the best approaches to elicit an
antitumor immune response (2). On the other hand, the
polarization of immunity towards the cellular arm plays an
essential role in defense against tumor cells (4). Adjuvants
are useful materials to induce an appropriate response
in clinical vaccines (5,6). Unfortunately, alum, the only
adjuvant approved worldwide for human use, is able to
enhance only the Th2-specific response (7). Meanwhile,
strong Th1 adjuvants, like complete Freund’s adjuvant,
cannot be tolerated by humans (8). Thus, researching
new and safe adjuvants for induction of robust cellular
immunity would be a logical decision.
* Correspondence: meysamabtahi@hotmail.com
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Some evidence has suggested that naloxone (NLX), an
opioid receptor antagonist, acts as an appropriate adjuvant
in enhancing vaccine-induced cellular immunity and
Th1 immune responses against viruses and intracellular
bacteria or parasites (9–13).
It is worth indicating that breast cancer is the most
commonly diagnosed form of cancer and the second
leading cause of death among Western women (14). The
4T1 mammary carcinoma is an easily transplantable,
highly tumorigenic, and invasive tumor cell line that can
be used as an experimental animal model for human
mammary cancer (15,16). The 4T1 cell lines, unlike most
tumor models, can spontaneously metastasize from the
primary tumor in the mammary gland to multiple distant
sites like lymph nodes, blood, liver, lung, brain, and bone,
in a very similar manner to human mammary cancer
(15,17).
This study was carried out to investigate the efficacy of
a new vaccine against breast cancer, made by mixing the
extract of heated 4T1 cells and NLX, as an adjuvant.
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2. Materials and methods
2.1. Materials
Fetal calf serum, Dulbecco’s modified Eagle’s medium
(DMEM), and RPMI 1640 medium were purchased from
GIBCO/Life Technologies Inc. (Gaithersburg, MD, USA).
In addition, naloxone, 3-[4,5-dimethylthiazol-2-yl]-2,5diphenyl tetrazolium bromide (MTT), nitro tetrazolium
blue chloride (NBT), dimethyl sulfoxide (DMSO),
phytohemagglutinin (PHA), dioxane, and phosphatebuffered saline (PBS) were obtained from Sigma-Aldrich
(St. Louis, MO, USA). Enzyme-linked immunosorbent
assay (ELISA) kits were procured from QIAGEN (Hilden,
Germany).
2.2. Cells and culture conditions
4T1 cells were supplied from the Pasteur Institute of Iran.
The cells were cultured at 37 °C in a humidified atmosphere
with 5% CO2 and maintained in monolayer cultures in
DMEM supplemented with 10% FBS.
2.3. Animals and tumor challenge
Female BALB/c mice of 6–8 weeks old were brought from
the Pasteur Institute of Iran. The mice were maintained
under constant temperature (22–24 °C) and a 12-h light/
dark cycle, and they received food and water ad libitum.
Animal welfare was observed in compliance with the
regulations of the Ministry of Health and Medical
Education of Iran, approved by the medical ethics
committee of the university for animal studies. Animals
were allowed to rest for 1 week before any treatment and
were then challenged subcutaneously in the right flanks
with 1 × 105 viable tumor cells in 50 µL of PBS. Tumor
growth was monitored every 5 days by a caliper. Tumor
volume in mm3 was estimated by using the formula of an
ellipsoid (length × width × height × 0.5236).
2.4. Vaccination of the mice
Vaccination was initiated when all animals developed
a palpable tumor. At this time, the mice were randomly
divided into 3 groups. Each group had 10 animals
with tumors and all vaccines were administrated by
subcutaneous injection to the left flank. In the first group,
with the control tumor mice, the animals received 100 µL
of PBS twice at a 1-week interval. In the second group, the
heated 4T1-treated group, the mice were immunized twice
at a 1-week interval with the frozen and thawed extract
of 103 heated 4T1 cells in 100 µL of volume. The heated
4T1 cells were provided by the exposure of 4T1 cell lines
to nonlethal heat shock (43 °C, 30 min). Finally, in the last
group, with the combined NLX and heated 4T1-treated
mice, the animals were vaccinated twice at a 1-week
interval with the frozen and thawed extract of 103 heated
4T1 cells and NLX (6 mg/kg) in 100 µL of volume. One
week after the last immunotherapy, half of the mice were
euthanized in order to evaluate their immune responses.

2.5. Splenocyte proliferation
The proliferation potential of lymphocytes in the splenocyte
population was evaluated by MTT assay. In brief, spleen
cells were aseptically isolated from mice at the time of
bleeding. The single-cell suspensions of splenocytes were
prepared in RPMI 1640 medium, supplemented with 10%
fetal calf serum, and red blood cells (RBCs) were removed
by RBC lysis buffer (18). The splenocytes were plated in
96-well flat-bottomed plates in RPMI 1640 medium,
supplemented with 10% fetal calf serum (1 × 105 cells 100
µL–1 well–1) and stimulated with 50 µL of PHA solution (1
mg/mL) or medium alone. After 72 h of incubation, the
cultures were pulsed with 20 µL of the MTT solution (5
mg/mL) for 4 h at 37 °C. Then 150 mL of DMSO was added
and shaken vigorously to dissolve the formazan crystals.
The optical density (OD) at 550 nm was measured using a
microplate reader (Dynatech, Denkendorf, Germany). The
experiments were done in triplicate sets. The results were
expressed as the proliferation index according to the ratio
of the OD550 of stimulated cells with PHA to the OD550 of
nonstimulated cells (18).
2.6. Cytokine production
The splenocytes (2 × 106 cells/mL) were incubated in 24well plates and pulsed with 50 µL of PHA solution (1 mg/
mL). The culture supernatants were collected after 72 h.
IFN-γ, IL-4, IL-10, and TGF-β production was assumed by
ELISA according to the manufacturer’s instructions.
2.7. Respiratory burst in the splenocyte population
Respiratory burst of phagocytic cells in the splenocyte
population was checked by using NBT dye reduction as
described previously (19). In brief, 100 µL of the suspension
of splenocytes with 0.1 mL of S. aureus suspension (108
cell/mL) and 0.1 mL of 0.1% NBT in PBS (pH 7.4) were
mixed. The mixture was incubated at room temperature
for 15 min and subsequently kept at 37 °C for an additional
15 min. The reduced dye was extracted in dioxane and
quantitated at 520 nm.
2.8. Statistical analysis
The statistical analysis was performed with the Kruskal–
Wallis test, followed by pair-wise comparisons using the
Mann–Whitney U test with Bonferroni adjustment. The
results were shown as mean ± SD. P < 0.05 was considered
statistically significant.
3. Results
Following tumor induction, mice were monitored every 5
days for the first signs of palpable tumors. All immunization
protocols were started on day 12 after tumor induction,
when individual mice developed a palpable tumor, and
continued to day 59, when all mice in the groups died. As
illustrated in Figure 1, mice that received the combined
heated 4T1 and NLX showed a more favorable survival
curve compared to mice in other groups. At least 20% of
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Figure 1. Survival of BALB/c mice challenged with 4T1 cells
after immunotherapy. Immunotherapy was started when all
animals had developed a palpable tumor. Combined extract of
heated 4T1 and naloxone (NLX) led to more favorable outcome
compared to other groups.

The ex vivo cytokine assay demonstrated that combined
immunization significantly upregulated the secretion
of IFN-γ and conversely downregulated the secretion
of IL-4, IL-10, and TGF-β in the splenocyte population
compared to the splenocytes from other groups (Figure 3).
Although a similar pattern of change in the secretion of
these cytokines was observed in heated 4T1 immunized
mice compared to the control group, these changes, except
for IL-10, were not statistically significant. Moreover,
a significant increase in splenocyte proliferation was
observed in mice with tumors that received the combined
heated 4T1 and NLX compared to other animals (Figure
4A).
350
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**

mice in the combined immunization group were alive until
day 58 after tumor induction, while all mice in the group
treated with heated 4T1 alone were dead by day 45 after
tumor induction. The survival rate of the control tumor
mice was very poor compared to other groups as all mice
in this group were dead by day 36 after tumor induction.
Moreover, tumors developed at a significantly slower
rate in the mice that received the combined immunotherapy
in comparison with other groups (Figure 2). Mice in this
group showed a significant reduction in tumor growth
rate from day 27 after tumor induction compared to other
groups. The tumor volume changes were not statistically
different between mice that received the extract of heated
4T1 and control tumor mice (Figure 2).
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Figure 2. Evaluation of mammary tumor size after
immunotherapy. Tumor volume was estimated as detailed in
Section 2. Combined extract of heated 4T1 and NLX decreased
tumor growth rate more profoundly than in other groups (*P <
0.05 versus control tumor mice and/or mice with tumors that
received only the extract of heated 4T1).
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Figure 3. Effects of immunotherapy on cytokine production
of splenocyte population. One half of mice in each group were
euthanized 1 week after last immunotherapy and splenocytes
were isolated and cultured for 72 h as described in Section 2 (*P
< 0.01; **P < 0.001 versus control tumor mice and/or mice with
tumors that received only the extract of heated 4T1; #P < 0.05
versus control tumor mice).

As shown in Figure 4B, the respiratory burst was
significantly increased in the splenocytes from the
combined immunized mice with mammary tumors and
the mice with mammary tumors that received only heated
4T1, as compared to control tumor mice. This increase
was significantly more profound in mice with tumors that
received combination immunotherapy as compared to
mice with tumors that received only the extract of heated
4T1.
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4. Discussion
The malignant tumors induced by 4T1 cells are able to
frequently grow and evade destruction by the immune
responses because of their low immunogenicity (20,21). In
this regard, enhancement of the immunogenicity of 4T1
cells was considered as the first goal of the current study.
Heat shock proteins (HSPs) are highly conserved
housekeeping proteins, found in all organisms, that
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Figure 4. Modulation of splenocyte proliferation (A) and respiratory burst (B) after immunotherapy. Lymphocyte
proliferation in splenocytes was determined by MTT test as described in Section 2 (A). The respiratory burst of phagocyte
cells in splenocytes was assumed by NBT reduction assay as detailed in Section 2 (B) (*P < 0.001 versus control tumor
mice and/or mice with tumors that received only the extract of heated 4T1).

upregulate under a wide variety of physiological and
pathological stimuli such as heat shock (22,23). The
extracellular and membrane-bound HSPs, especially
Hsp70 families, participate in binding and presenting
tumor antigens to the antigen-presenting cells as
a mechanism for host-priming of T-cell-mediated
antitumor immunity (24–26). A prior study revealed that
the exposure of 4T1 cell lines to nonlethal heat shock
induced the surface expression of Hsp72, a member of the
Hsp70 family, and concurrently reduced the growth and
metastatic potential of these cells in vivo (27). Accordingly,
the 4T1 cells used in the current study were sublethally
heated before undergoing the freeze/thaw procedure.
Based on the results, vaccination with the extract of heated
4T1 cells could reduce the tumor growth rate and increase
the survivability of the mice with breast tumors; however,
these changes were not significant. Nevertheless, the
vaccine made with the extract of heated 4T1 cells and NLX
as an adjuvant significantly reduced the tumor growth
rate, and consequently the survivability of these mice
significantly increased.
The previous available data showed that the interaction
between immune and nervous systems plays a substantial
role in the fate of immune responses (28,29). Naloxone is
routinely used to rapidly and safely reverse opioid-induced
respiratory depression (30). It is now clear that opioid
receptors, particularly κ- and δ-opioid receptors, are
expressed in immune cells. Opioid receptors can modulate
both innate and acquired immune responses (31–33).
Earlier evidence suggests that naloxone may induce a
proinflammatory milieu by increasing the release of local

proinflammatory neuropeptides, such as substance P, from
the nerve fibers or via a direct effect on innate immune
cells, including monocytes, macrophages, and dendritic
cells (9,34,35). Antigens in this proinflammatory milieu
can promote specific immunity toward cell-mediated
immunity and a Th1 pattern response (9,36). On the other
hand, neuropeptides may promote the maturation and
migration of local antigen-presenting cells to the draining
lymph nodes and skew immune responses toward a Th1
pattern (10).
The combined heated 4T1 cells and NLX significantly
increased splenocytes’ proliferative response, more so than
that observed after treatment with heated 4T1 cells. In this
regard, previous reports showed that the opioid possesses
an antiproliferative effect on T-cells, and, in contrast,
naloxone accelerates the mitogen-induced splenocyte
proliferation (10,37,38).
It is clear that IFN-γ production by the immune system
correlates with antitumor responses (3). The obtained
results showed that IFN-γ production in the splenocyte
population was significantly increased more than that
observed in other groups. Importantly, the level of IFN-γ
did not show any significant difference among the control
tumor group and the mice immunized with heated 4T1.
Tumors are able to evade immunity by secreting some
mediators like TGF-β and IL-10. TGF-β and IL-10 tend to
inhibit the proliferation and activation of lymphocytes and
macrophages and consequently suppress cell-mediated
immunity, and they are required to control tumor growth
(37,39). Both cytokines can induce the development of
regulatory T cells, which have been found in a variety
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of tumors, and may suppress T cell responses to tumors.
Interestingly, regulatory T cells are the other source of
TGF-β and IL-10 (39). Besides TGF-β and IL-10, IL-4
can diminish the essential arms of antitumor immunity
including macrophages and Th1 responses. Moreover, it
seems that IL-4 directly promotes the tumor cell growth
in human breast cancer (40). Our data demonstrated that
the combined heated 4T1 and NLX significantly lowered
the levels of TGF-β, IL-10, and IL-4 further than in other
groups.
Previous works showed that IFN-γ-activated
macrophages display various antitumor functions, such
as profound production of reactive oxygen species (ROS)
(41). Unfortunately, malignant tumors may suppress
macrophage activation and promote macrophages to
secrete soluble factors such as TGF-β, which confers a
local state for tumor growth (42). It has been reported that
the injection of IL-4-treated monocytes into the mammary
fat pads of mice with 4T1 cell-induced tumors increased

the solid tumor growth and lung metastasis of 4T1 cells
(42). In the current survey, the NBT reduction assay in
splenocytes was used to estimate the level of production
of ROS by macrophages in the tumor microenvironment.
The findings showed that the production of the ROS was
significantly increased in vaccine-treated mice compared
with the control tumor mice.
As a result, it was concluded that the combined NLX
and heated 4T1 cells promote beneficial outcomes in
the mouse model of breast cancer. It is of note that the
immunogenicity of 4T1 cells is very low (20,21). Therefore,
the achieved findings are beneficial. However, it should be
stated that this survey is a preliminary study, and further
studies need to be designed and developed.
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